Seeing is believing: Impact of social modeling on placebo and nocebo responding
This study investigated the impact of the social modeling of side effects following placebo medication ingestion on the nocebo and placebo effect. It also investigated whether medication branding (brand or generic labeling) moderated social modeling effects. Eighty-two university students took part in the study which was purportedly investigating the impact of fast-acting beta-blocker medications (actually placebos) on preexamination anxiety. After taking the medication, participants were randomized to either witness a female confederate report experiencing side effects or no side effects after taking the same medication. Differences in symptom reporting, blood pressure, heart rate, and anxiety were assessed between the social modeling of side effects and no modeling groups. Seeing a female confederate report side effects reduced the placebo effect in systolic (p = .009) and diastolic blood pressure (p = .033). Seeing a female confederate report side effects also increased both total reported symptoms (mean [SE] 7.35 [.54] vs. 5.16 [0.53] p = .005) and symptoms attributed to the medication (5.27 [0.60] vs. 3.04 [0.59] p = .01), although the effect on symptoms was only seen in female participants. Females who saw the confederate report side effects reported approximately twice the number of symptoms as those in the no modeling group. Social modeling did not affect heart rate or anxiety. Medication branding did not influence placebo or nocebo outcomes. The social modeling of symptoms can substantially reduce or eliminate the placebo effect. Viewing a female confederate display symptoms after taking the same medication increases symptom reporting in females..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Health psychology - 34(2015), 8, Seite 880-885 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Faasse, Kate [VerfasserIn] |
|---|
| Links: |
|---|
| RVK: |
|---|
| doi: |
10.1037/hea0000199 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1956562834 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1956562834 | ||
| 003 | DE-627 | ||
| 005 | 20230517155949.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1037/hea0000199 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1956562834 | ||
| 035 | |a (DE-599)GBVOLC1956562834 | ||
| 035 | |a (PRQ)c2172-5189bf4bac4ab35dd69c4718ca0b00f70df77faa5fc0d3a1e288cbe0ece6ee7b0 | ||
| 035 | |a (KEY)0121364420150000034000800880seeingisbelievingimpactofsocialmodelingonplaceboan | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 150 |q ZDB |
| 084 | |a CL 1000: |q AVZ |2 rvk | ||
| 084 | |a 77.00 |2 bkl | ||
| 100 | 1 | |a Faasse, Kate |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Seeing is believing: Impact of social modeling on placebo and nocebo responding |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a This study investigated the impact of the social modeling of side effects following placebo medication ingestion on the nocebo and placebo effect. It also investigated whether medication branding (brand or generic labeling) moderated social modeling effects. Eighty-two university students took part in the study which was purportedly investigating the impact of fast-acting beta-blocker medications (actually placebos) on preexamination anxiety. After taking the medication, participants were randomized to either witness a female confederate report experiencing side effects or no side effects after taking the same medication. Differences in symptom reporting, blood pressure, heart rate, and anxiety were assessed between the social modeling of side effects and no modeling groups. Seeing a female confederate report side effects reduced the placebo effect in systolic (p = .009) and diastolic blood pressure (p = .033). Seeing a female confederate report side effects also increased both total reported symptoms (mean [SE] 7.35 [.54] vs. 5.16 [0.53] p = .005) and symptoms attributed to the medication (5.27 [0.60] vs. 3.04 [0.59] p = .01), although the effect on symptoms was only seen in female participants. Females who saw the confederate report side effects reported approximately twice the number of symptoms as those in the no modeling group. Social modeling did not affect heart rate or anxiety. Medication branding did not influence placebo or nocebo outcomes. The social modeling of symptoms can substantially reduce or eliminate the placebo effect. Viewing a female confederate display symptoms after taking the same medication increases symptom reporting in females. | ||
| 540 | |a Nutzungsrecht: © (c) 2015 APA, all rights reserved). | ||
| 650 | 4 | |a Comparative analysis | |
| 650 | 4 | |a Nocebo effect | |
| 650 | 4 | |a Adverse and side effects | |
| 650 | 4 | |a Forecasts and trends | |
| 650 | 4 | |a Placebo effect | |
| 650 | 4 | |a Drugs | |
| 650 | 4 | |a side effects | |
| 650 | 4 | |a Subjective Health Complaints Scale-Modified Version | |
| 650 | 4 | |a Adulthood (18 yrs & older) | |
| 650 | 4 | |a Human | |
| 650 | 4 | |a social modeling | |
| 650 | 4 | |a nocebo | |
| 650 | 4 | |a Quantitative Study | |
| 650 | 4 | |a symptoms | |
| 650 | 4 | |a Empirical Study | |
| 650 | 4 | |a placebo | |
| 650 | 4 | |a article | |
| 650 | 4 | |a Brief Cognitive Task | |
| 650 | 4 | |a Baseline Questionnaire | |
| 650 | 4 | |a Spielberger State Trait Anxiety Inventory | |
| 650 | 4 | |a New Zealand | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Male | |
| 700 | 1 | |a Grey, Andrew |4 oth | |
| 700 | 1 | |a Jordan, Rachel |4 oth | |
| 700 | 1 | |a Garland, Stacie |4 oth | |
| 700 | 1 | |a Petrie, Keith J |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Health psychology |d Washington, DC : American Psychological Association, 1982 |g 34(2015), 8, Seite 880-885 |w (DE-627)16657886X |w (DE-600)226369-5 |w (DE-576)015058204 |x 0278-6133 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2015 |g number:8 |g pages:880-885 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1037/hea0000199 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25545042 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1641020185 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PSY | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4310 | ||
| 936 | r | v | |a CL 1000: |
| 936 | b | k | |a 77.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 34 |j 2015 |e 8 |h 880-885 | ||